ReviewEssays in biochemistry2025
Single-cell RNA sequencing: enhancing the predictive accuracy of tumor immunotherapy efficacy.
Review in Essays in biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Functional and mechanistic inactivation of immune hubs orchestrates tumor development and progression in lung adenocarcinoma.Discover oncology · 2026Article
- Decoding the archipelago: single-cell biomarkers rechart the molecular geography of acute myeloid leukemia.Cell communication and signaling : CCS · 2026Review
- Peripheral blood biomarkers in PD-1/PD-L1 immunotherapy: distinguishing predictive from prognostic biomarkers.Frontiers in immunology · 2026Review
- Immunomodulation: precision targeting for restoring immune homeostasis and therapeutic applications.Essays in biochemistry · 2025Article
- CAR-γδ T cells: a new paradigm of programmable innate immune sentinels and their systemic applications in cancer and beyond.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The swift advancement of single-cell RNA sequencing (scRNA-seq) technology has furnished a crucial instrument for investigating the tumor microenvironment (TME) and its response to immunotherapy. As immunotherapy becomes increasingly prevalent, the challenge of accurately predicting its efficacy has emerged as a prominent focus in contemporary research. In recent years, the utilization of scRNA-seq in the context of immunotherapy has demonstrated promising potential, particularly in the realms of efficacy prediction and biomarker discovery. The heterogeneity of immune cells within the TME exerts intricate and multifaceted influences on treatment response, necessitating comprehensive investigation. Furthermore, the integration of biomaterials into tumor immunotherapy presents novel research opportunities in this domain. scRNA-seq technology offers a systematic approach to evaluating the modifications in the TME induced by biomaterials. This article aims to review the current state of scRNA-seq in the context of immunotherapy, identify existing challenges within related research, and propose future research directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.